Engineered extracellular vesicles for ischemic stroke treatment

作者：Huitong Ruan, Yong-Fang Li, Dandan Zheng, Lianfu Deng, Gang Chen, Xingcai Zhang, Yaohui Tang, Wenguo Cui · 发表于：The Innovation · 年份：2023 · DOI：10.1016/j.xinn.2023.100394 · 被引用次数：37 · 研究领域：Extracellular vesicles in disease、RNA Interference and Gene Delivery、MicroRNA in disease regulation

Dear Editor, Nanotechnology-based therapeutic strategies have been proven effective in diseases including cancer, infection, inflammation, etc.1Machtakova M. Thérien-Aubin H. Landfester K. Polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapeutic agents.Chem. Soc. Rev. 2022; 51: 128-152Crossref PubMed Google Scholar However, the application of nanotechnology is greatly restricted in the treatment of central nervous system (CNS) disorders due to physiological CNS barriers. For example, the blood-brain barrier (BBB) can be the “Maginot line” for pharmacologically active molecules, blocking them out of the CNS. Besides, the neuroinflammation and non-directional differentiation of neural stem cells (NSCs) during neurological disorders could also affect neuronal activity and even produce fibrotic scars, thus hindering the CNS regeneration process.2Dorrier C.E. Aran D. Haenelt E.A. et al.CNS fibroblasts form a fibrotic scar in response to immune cell infiltration.Nat. Neurosci. 2021; 24: 234-244Crossref PubMed Scopus (63) Google Scholar Synthetic nanocarriers, including liposomes, micelles, and nanoparticles, can be engineered through PEGylation and functional surface ligands to overcome the BBB and achieve CNS-targeted drug delivery.3Terstappen G.C. Meyer A.H. Bell R.D. Zhang W. Strategies for delivering therapeutics across the blood-brain barrier.Nat. Rev. Drug Discov. 2021; 20: 362-383Crossref PubMed Scopus (190) Google Scholar,4Ruan H. Yao ...